Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Research UK, Guardant Health Ink Research, Data Sharing Partnership

NEW YORK – Guardant Health, Cancer Research UK, and its innovation unit Cancer Research Horizons said Monday that they have entered a collaboration to explore the sharing of technologies, data, and insights to advance precision cancer detection and treatment.

The groups said the agreement will allow them to discuss opportunities for new collaboration, focusing primarily on clinical trials run by CRUK's Centre for Drug Development. This includes the DETERMINE trial — the first UK national precision medicine trial in rare cancers.

Additional potential projects may include sharing data and samples from the Cancer Research UK-funded research network to further develop and validate Guardant's liquid biopsy and tumor tissue sequencing technologies.

"Partnering with Guardant Health brings exciting potential for us to accelerate our work by applying best-in-class data-driven insights and technologies to our detection and treatment studies. Our Centre for Drug Development has an excellent track record in bringing novel therapeutics to first-in-human trials, and we look forward to seeing the positive impact this collaboration will have," Tony Hickson, chief business officer for Cancer Research UK and Cancer Research Horizons, said in a statement.

Financial terms of the agreement were not disclosed.